

CURIS INC
Form 3
August 15, 2007

FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0104
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *			2. Date of Event Requiring Statement	3. Issuer Name and Ticker or Trading Symbol	
Â RA CAPITAL MANAGEMENT, LLC			(Month/Day/Year)	CURIS INC [CRIS]	
(Last)	(First)	(Middle)		4. Relationship of Reporting Person(s) to Issuer	5. If Amendment, Date Original Filed(Month/Day/Year)
111 HUNTINGTON AVENUE, SUITE 610,Â				(Check all applicable)	
(Street)				<input type="checkbox"/> Director <input checked="" type="checkbox"/> 10% Owner	6. Individual or Joint/Group Filing(Check Applicable Line)
BOSTON,Â MAÂ 02199				<input type="checkbox"/> Officer (give title below) <input type="checkbox"/> Other (specify below)	<input type="checkbox"/> Form filed by One Reporting Person
(City)	(State)	(Zip)			<input checked="" type="checkbox"/> Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	7,520,564	I	See Footnote ⁽¹⁾

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)	3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)	4. Conversion or Exercise Price of Derivative	5. Ownership Form of Derivative Security:	6. Nature of Indirect Beneficial Ownership (Instr. 5)
--	--	---	---	---	---

Edgar Filing: CURIS INC - Form 3

	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Security	Direct (D) or Indirect (I) (Instr. 5)	
Warrants to Purchase Common Stock	Â (2)	08/08/2012	Common Stock	2,632,198	\$ 1.02	I	See Footnote (3)

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
RA CAPITAL MANAGEMENT, LLC 111 HUNTINGTON AVENUE, SUITE 610 BOSTON, MA 02199	Â	Â X	Â	Â
ALDRICH RICHARD C/O RA CAPITAL MANAGEMENT, LLC 111 HUNTINGTON AVENUE, SUITE 610 BOSTON, MA 02199	Â	Â X	Â	Â
Kolchinsky Peter C/O RA CAPITAL MANAGEMENT, LLC 111 HUNTINGTON AVENUE, SUITE 610 BOSTON, MA 02199	Â	Â X	Â	Â
RA Capital Biotech Fund II, L.P. C/O RA CAPITAL MANAGEMENT, LLC 111 HUNTINGTON AVENUE, SUITE 610 BOSTON, MA 02199	Â	Â X	Â	Â
RA Capital Biotech Fund LP C/O RA CAPITAL MANAGEMENT, LLC 111 HUNTINGTON AVENUE, SUITE 610 BOSTON, MA 02199	Â	Â X	Â	Â

Signatures

/s/ Peter Kolchinsky Manager of RA Capital Management LLC,	08/14/2007
**Signature of Reporting Person	Date
/s/ Richard H. Aldrich	08/14/2007
**Signature of Reporting Person	Date
/s/ Peter Kolchinsky	08/14/2007
**Signature of Reporting Person	Date
/s/ Peter Kolchinsky	08/14/2007
**Signature of Reporting Person	Date
/s/ Peter Kolchinsky	08/14/2007
**Signature of Reporting Person	Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) These shares represent 7,388,202 shares held by RA Capital Biotech Fund, L.P. ("Fund I"), and 132,362 shares held by RA Capital Biotech Fund II, L.P. ("Fund II"). RA Capital Management, LLC (the "General Partner") is the general partner of each of Fund I and Fund II, and Richard H. Aldrich and Peter Kolchinsky are the sole managers of RA Capital Management, LLC. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any.

(2) These warrants are exercisable for cash, provided, however, that the warrants are not exercisable to the extent the holder of any such warrant, together with any affiliates, holds or beneficially owns more than 9.99% of the outstanding Common Stock of the issuer, unless such restriction is waived by the holder upon not less than 61 days written notice to the issuer.

(3) These warrants represent the right for RA Capital Biotech Fund, L.P. ("Fund I") to acquire 2,585,871 additional shares of Common Stock and for RA Capital Biotech Fund II, L.P. ("Fund II") to acquire 46,327 additional shares of Common Stock, in each case upon the terms and conditions set forth in such warrant. RA Capital Management, LLC (the "General Partner") is the general partner of each of Fund I and Fund II, and Richard H. Aldrich and Peter Kolchinsky are the sole managers of RA Capital Management, LLC. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.